Malaysia Oncology Drugs Market Report 2022 to 2030

Malaysia Oncology Drugs Market Analysis

$ 3999

By 2030, it is anticipated that the Malaysia oncology drugs market will reach a value of $xx Mn from $315.83 Mn in 2022, growing at a CAGR of xx% during 2022-30. The oncology drugs market in Malaysia is dominated by a few domestic pharmaceutical companies such as Pharmaniaga Berhad, Biocon Sdn Bhd, and Duopharma Biotech. The oncology market in Malaysia is segmented into different therapeutic areas and different treatment types. The major factors affecting the Malaysia oncology drugs market are the increasing disease burden of non-communicable diseases like cancer and the lack of healthcare facilities for cancer treatment in most areas of Malaysia.

ID: IN10MYPH018 CATEGORY: Pharmaceuticals GEOGRAPHY: Malaysia AUTHOR: Dr. Vishwa Modhia

Buy Now

Malaysia Oncology Drugs Market Analysis Summary

By 2030, it is anticipated that the Malaysia oncology drugs market will reach a value of $xx Mn from $315.83 Mn in 2022, growing at a CAGR of xx% during 2022-30.

Malaysia is a Southeast Asian federation of 13 states and three federal areas. It is a developing country with an upper middle-income. Biosimilars, which are less expensive copies of biological medications, are becoming increasingly popular in Malaysia. This is due to the high cost of original biologic medications and the aim to improve cancer therapy availability.

Malaysia's government has been investing in the healthcare industry and working to improve access to cancer treatment. Malaysia's government devotes 4.1% of its GDP to healthcare.

malaysia oncology drugs market analysis

Market Dynamics

Market Growth Drivers Analysis

This has included boosting the number of oncology centers and offering cancer medicine subsidies. Malaysians have a high per capita income, which increases their purchasing power in the healthcare and pharmaceutical industries. In Malaysia, investment is encouraged by the expansion of the local financial sector and access to FDIs, which boosts the country's economy. Cancer incidence has been increasing in Malaysia in recent years, with the National Cancer Registry reporting an average yearly increase of 3.4 % between 2007 and 2016. This has boosted the demand for oncology medications. These aspects could boost Malaysia's oncology drugs market.

Market Restraints

NCDs such as high blood pressure, diabetes, and many malignancies go untreated due to a lack of knowledge and education. Malaysia has persistent geographical imbalances, which causes the distribution of cancer medications to be uneven across the country. These factors may deter new entrants into the Malaysia oncology drugs market.

Competitive Landscape

Key Players

Pharmaniaga Berhad (MYS)
Kotra Pharma (MYS)
Duopharma Biotech (MYS)
Biocon Sdn Bhd (MYS)
Hoffmann-La Roche Ltd.
Novartis AG
Gilead Sciences Inc.
Bayer AG

Recent Notable Updates

December 2022: The Department of Islamic Development Malaysia recognized Duopharma Biotech as the first pharmaceutical company to gain Halal certification for an oncology product (JAKIM). The Halal oncology product is manufactured at Duopharma Biotech's Highly Potent Active Pharmaceutical Ingredients (HAPI) facility in Glenmarie, Shah Alam, and is supplied to both government and private healthcare hospitals in Malaysia. It has recently been approved for export to Brunei and Singapore. Currently, the medicine is approved as an adjuvant treatment for postmenopausal women with early breast cancer and as a first-line treatment for postmenopausal women with metastatic breast cancer.

Healthcare Policies and Reimbursement Scenarios

In Malaysia, the National Pharmaceutical Regulatory Agency (NPRA), which is part of the Ministry of Health Malaysia, is in charge of oncology drug registration and regulation. Furthermore, the Malaysian National Cancer Institute (NCI) is involved in the regulation of cancer medications in Malaysia. The National Cancer Institute (NCI) is a government-funded research organization that performs clinical trials and provides cancer therapy and management advice. In addition, the agency works with foreign regulatory organizations such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to ensure that its regulatory standards are aligned with worldwide best practices.

The Ministry of Health (MOH) in Malaysia maintains a National Drug Formulary (NDF) that identifies all pharmaceuticals licensed for use in the public healthcare system, including oncology drugs. Some of these pharmaceuticals are offered to qualified patients for free or at a reduced cost through the government's healthcare programs. Private health insurance carriers in Malaysia may give coverage for oncology drugs to patients who are not eligible for government healthcare programs or who require drugs that are not available in the public healthcare system.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Oncology Drugs Market Segmentation

By Drug class

Cytotoxic drugs
- Alkylating agents
- Antimetabolites
- Others
Targeted drugs
- Monoclonal antibodies
- Others
Hormonal drugs
Others

By Therapy

Chemotherapy
Targeted therapy
Immunotherapy

By Indication

Lung cancer
Stomach cancer
Colorectal cancer
Breast cancer
Prostate cancer
Others

By Dosage form

Solid
- Tablets
- Capsules
Liquid
Injectable
- Prefilled syringes
- Others

By Distribution channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.